EXJADE Provides Total Body Iron Chelation to Transfused Patients With β-Thalassemia

In regularly transfused patients with β-thalassemia, EXJADE therapy has been shown to be effective in reducing liver iron concentration and serum ferritin levels, as well as cardiac iron toxicity measured by T2* values

Learn more about the cardiac substudy of the EPIC clinical trial.

SAFETY PROFILE ACROSS ANEMIAS

Learn more